期刊文献+

胰岛素抵抗与冠状动脉病变及微量白蛋白尿的相关分析 被引量:1

Relationship of insulin resistance to coronary lesion and micro-albuminuria
暂未订购
导出
摘要 目的探讨胰岛素抵抗(IR)与冠状动脉病变及微量白蛋白尿(MAU)之间的关系。方法连续收集经冠状动脉造影证实至少有1支血管狭窄≥50%的123例患者作为研究对象,均行口服葡萄糖耐量(OGTT)试验及MAU、胰岛素水平测定。以内环境稳定评估模型(HOMA)值作为评价IR程度指标,对MAU及冠状动脉病变程度行相关分析。结果随着IR程度的增高,MAU水平逐渐增高,冠状动脉病变程度逐渐增高。IR与MAU及冠状动脉病变程度具有明显相关性。结论IR和动脉粥样硬化相关,在冠心病的预防和治疗中要重视IR。 Objective To investigate the relationship of insulin resistance (IR) to coronary lesion and microalbuminuria. Methods One hundred and thirteen consective patients with coronary heart disease (CHD) confirmed by angiography were included. Each patient received oral glucose tolerance test (OGTT) and plasma insulin and urine albumin level were measured. Value of homeostasis model assessment (HOMA) was adopted as the IR index. The relationship of IR to coronary lesion and micro-albuminuria was studied by correlation analysis. Results micro-albuminuria and coronary lesion aggravated gradually with the increase of the IR. IR was significantly correlated with the severity of coronary lesion and micro-albuminuria. Conclusions IR may be an etiologic mechanism for coronary atherosclerosis, and it should be reduced to in the prevention and treatment of CHD.
作者 王宇 林树无
出处 《中国心血管杂志》 2008年第1期21-23,共3页 Chinese Journal of Cardiovascular Medicine
关键词 冠状动脉疾病 胰岛素抵抗 微量白蛋白尿 Coronary heart disease Insulin resistance Micro-albuminuria
  • 相关文献

参考文献10

  • 1Mogensen C. mMicroalbuminuria, blood pressure and diabetic renal diseases origin and development of ideas [J]. Diabetotogia, 1999,42:263-285.
  • 2Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease [J]. Am J Cardiol,1983,51:606.
  • 3Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J]. Diabetologia, 1985,28:412-419.
  • 4Nordt T, Sawa H, Fujii S, et al. Induction of plasminogen activator inhibitor type 1 ( PAI-1 ) by proinsulin and insulin in vivo[J]. Circulation, 1995,91 : 764.
  • 5Kihara S, Quchi N, Funahashi T, et al. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinas in human aortic smooth muscular cells [J]. Arteriosclerosis, 1998,1:36 : 163-168.
  • 6Rifdind BM. High-density Lipoprotein cholesterol and coronary artery disease:survey of the evidence[J]. Am J Cardiol, 1999,66 : 3A.
  • 7杨亦彬,陈忠霞,徐昆.糖尿病血管内皮损害标志物的检测及其与尿白蛋白的关系[J].医师进修杂志,2005,28(5):21-23. 被引量:7
  • 8姜华,吴建国,张我素.冠心病合并Ⅱ型糖尿病患者冠状动脉病变特点[J].中国介入心脏病学杂志,2000,8(3):118-120. 被引量:78
  • 9Asaki A, Oikana S, Toyota T. Microalbuminuria is closely related TO diabetic macroangiopathy [J]. Diabetes Res Clin Pract, 1999,44 : 35-40.
  • 10Stern MP. Diabetes and cardiovascular disease: The "common soil" hypothesis[J]. Diabetes, 1995,44 : 374- 396.

二级参考文献13

  • 1周继红,朱佩芳,刘怀林,刘大维,邹用志,杨自力.大鼠烧冲复合伤后PAM和PMN呼吸爆发功能及循环内皮细胞变化[J].第三军医大学学报,1994,16(1):61-62. 被引量:10
  • 2Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diaboetes mellitus provisional report of a WHO consultation. Diabet Med,1998,15(7) :539 - 553.
  • 3Jacobon SH, Egberg N, Hylander B, et al. Correlation between soluble markers of endothelial dysfuntion in patients with renal failure. Am JNephrol,2002, 22(1) :42 - 47.
  • 4Dedov Ⅱ, Shestakov MV, Kochemasova TV, et al. Endothelial dysfunction in the development of vascular complications in diabetes mellitus.Ross Fiziol Zh Im I M Sechenova,2001,87(8): 1 073- 1 084.
  • 5Segal MS, Bihorac A, Koc M. Circulating endothelial cells: tea leaves for renal disease. Am J Physiol Ren Physiol,2002,283(1): 11 - 19.
  • 6Thkahashi H, Harker LA. Measuremant of human endothelial cells in whole blood. Thromb Res, 1983,31:1 - 12.
  • 7Koc M, Bihorac A, Segal MS. Circulating endothelial cells as potential markers of the state of the endothelium in hemodialysis patients. Am JKidney Dis,2003,42(4) :704 - 712.
  • 8Kessler L, Wiesel ML, Attali P, et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab, 1998,24(4) :327 - 336.
  • 9Morise T, Koni I,Takeuchi Y,et al. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in non insulin dependent diatetes mellitus patients. Diabetes Care, 1995, 18(1): 87 - 89.
  • 10HiranoT, OokuboK, KashiwazakiK,etal. Vascular endothelial markers, yon Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta,2000,299(1-2):65-75.

共引文献81

同被引文献10

  • 1Hostetter TH. Prevention of the development and progression of renal desease. J Am Soc Nephrol,2003,147 Suppl 2:144-147.
  • 2Clark R, Daly L, Robinson K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med, 1991,324 : 1149-1155.
  • 3Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atheroselerosis, 1993, 103 : 149-157.
  • 4Buysschaert M, Dramais AS, Wallemacq PE,et al. Hyperhomocysteinemia in Type 2 Diabetes: Relationship to maeroangiopathy, nephropathy, and insulin resistance. Diabetes Care,2000, 23:1816-1822.
  • 5Aso Y, Yoshida N, Okumura K, et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clinica Chimica Acta, 2004, 348:139-145.
  • 6Brazionis L, Rowley K, Itsiopoulos C, et al. Homocysteine and diabetic retinopathy. Diabetes Care, 2008, 31 : 50-56.
  • 7Mann JFE, Sheridan P, McQueen M J, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant, 2008, 23: 645-653.
  • 8Genest J, Frohlich J, Steiner G, et al. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol, 2004,93 : 848-853.
  • 9Gerstein HC. Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med, 1997,1:87-88.
  • 10高妍.糖尿病与高血压的治疗进展[J].中华内科杂志,1999,38(10):714-716. 被引量:66

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部